Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target

Relapsed prostate cancer (CaP), usually treated with androgen deprivation therapy, acquires resistance to develop into lethal metastatic castration-resistant CaP. The cause of resistance remains elusive, and the lack of biomarkers predictive of castration-resistance emergence is a stumbling block in managing the disease. We provide strong evidence that Myeloid differentiation factor-2 (MD2) plays a critical role in metastasis and CaP progression. Analysis of tumor genomic data and IHC of tumors showed a high frequency of MD2 amplification and association with poor overall survival in patients. The Decipher-genomic test validated the potential of MD2 in predicting metastasis. In vitro studies demonstrated that MD2 confers invasiveness by activating MAPK and NF-kB signaling pathways. Furthermore, we show that metastatic cells release MD2 (sMD2). We measured serum-sMD2 in patients and found that the level is correlated to disease extent. We determined the significance of MD2 as a therapeutic target and found that targeting MD2 significantly inhibited metastasis in a murine model. We conclude that MD2 predicts metastatic behavior and serum-MD2 is a non-invasive biomarker for tumor burden, whereas MD2 presence on prostate biopsy predicts adverse disease outcome. We suggest MD2-targeted therapies could be developed as potential treatments for aggressive metastatic disease.

[1]  A. Rao,et al.  Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor , 2020, Molecular Cancer Therapeutics.

[2]  W. Ricke,et al.  Development and prevalence of castration-resistant prostate cancer subtypes , 2020, Neoplasia.

[3]  C. Ren,et al.  Roles of PTBP1 in alternative splicing, glycolysis, and oncogensis , 2020, Journal of Zhejiang University-SCIENCE B.

[4]  C. Morrissey,et al.  COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer , 2019, Molecular Cancer Therapeutics.

[5]  A. Evans,et al.  Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. , 2019, European urology oncology.

[6]  K. Pienta,et al.  Metastatic prostate cancer remains incurable, why? , 2018, Asian journal of urology.

[7]  Luke H. Hoeppner,et al.  BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models , 2018, Clinical Cancer Research.

[8]  T. Ou,et al.  The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer , 2018, Front. Immunol..

[9]  D. Cahill,et al.  Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices , 2018, Translational andrology and urology.

[10]  Luke H. Hoeppner,et al.  Fishing for cures: The alLURE of using zebrafish to develop precision oncology therapies , 2017, npj Precision Oncology.

[11]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[12]  D. Penson,et al.  A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy , 2015, PLoS currents.

[13]  S. Raghav,et al.  TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells , 2015, The Prostate.

[14]  M. Menon,et al.  Oncologic outcomes at 10 years following robotic radical prostatectomy. , 2015, European urology.

[15]  M. Kolodziej.  Management of biochemically recurrent prostate cancer following local therapy. , 2015, The American journal of managed care.

[16]  H. Aburatani,et al.  ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: Study in African‐American and Caucasian prostate cancer models , 2014, International journal of cancer.

[17]  Ram Krishna Thakur,et al.  Non-metastatic 2 (NME2)-mediated suppression of lung cancer metastasis involves transcriptional regulation of key cell adhesion factor vinculin , 2014, Nucleic acids research.

[18]  E. Bahraoui,et al.  HIV-1 Tat protein binds to TLR4-MD2 and signals to induce TNF-α and IL-10 , 2013, Retrovirology.

[19]  Luke H. Hoeppner,et al.  Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin. , 2013, Cancer research.

[20]  V. Adhami,et al.  The S100A4 Oncoprotein Promotes Prostate Tumorigenesis in a Transgenic Mouse Model: Regulating NFκB through the RAGE Receptor. , 2013, Genes & cancer.

[21]  H. Mukhtar,et al.  BMI1 Polycomb Group Protein Acts as a Master Switch for Growth and Death of Tumor Cells: Regulates TCF4-Transcriptional Factor-Induced BCL2 Signaling , 2013, PloS one.

[22]  Anton J. Enright,et al.  The zebrafish reference genome sequence and its relationship to the human genome , 2013, Nature.

[23]  Luke H. Hoeppner,et al.  Revealing the role of phospholipase Cβ3 in the regulation of VEGF-induced vascular permeability. , 2012, Blood.

[24]  F. Vizoso,et al.  Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence , 2011, Cancer Immunology, Immunotherapy.

[25]  R. Buscà,et al.  HIF‐1α mediates the induction of IL‐8 and VEGF expression on infection with Afa/Dr diffusely adhering E. coli and promotes EMT‐like behaviour , 2010, Cellular microbiology.

[26]  Pierre I Karakiewicz,et al.  Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. , 2009, The Journal of urology.

[27]  Hayyoung Lee,et al.  Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran , 2007, Cell.

[28]  S. Araki,et al.  Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. , 2007, Cancer research.

[29]  Thomas J. Smith,et al.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  U. Ferreira,et al.  Seminal vesicle invasion in radical prostatectomies: Which is the most common route of invasion? , 2007, International Urology and Nephrology.

[31]  S. Akira,et al.  Essential role of MD-2 in LPS responsiveness and TLR4 distribution , 2002, Nature Immunology.

[32]  M. Loda,et al.  Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer , 2000, Oncogene.

[33]  M. Baghdadi,et al.  Biochemical recurrence after radical prostatectomy: what does it mean? , 2018, International braz j urol : official journal of the Brazilian Society of Urology.

[34]  P. Carroll,et al.  NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[35]  Susan R. Quinn,et al.  Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages. , 2015, Cell metabolism.

[36]  F. Luscinskas,et al.  Assays of transendothelial migration in vitro. , 2008, Methods in enzymology.

[37]  A. Partin,et al.  Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications. , 2000, Reviews in urology.